(Q57634693)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20508621%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

title

A conceptual framework for the identification of candidate drugs and drug targets in acute promyelocytic leukemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20508621%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

1 reference

acute promyelocytic leukemia

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20508621%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Bo Torben Porse

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20508621%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Kim Theilgaard-Mönch

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20508621%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

author name string

T T Marstrand

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20508621%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

R Borup

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20508621%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

A Willer

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20508621%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

N Borregaard

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20508621%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

publication date

27 May 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20508621%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20508621%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20508621%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20508621%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

page(s)

1265-1275

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20508621%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2010.95

3 February 2020

exact match

0 references

cites work

Acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

Prognostically useful gene-expression profiles in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

Retinoic acid receptors, hematopoiesis and leukemogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

Acute promyelocytic leukemia: from highly fatal to highly curable

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

Reconstructing a disease: What essential features of the retinoic acid receptor fusion oncoproteins generate acute promyelocytic leukemia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

Role of the polycomb repressive complex 2 in acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

PML-RARA-RXR oligomers mediate retinoid and rexinoid/cAMP cross-talk in acute promyelocytic leukemia cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

Functional analysis of human hematopoietic stem cell gene expression using zebrafish

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

The transcriptional program of terminal granulocytic differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

Bioconductor: open software development for computational biology and bioinformatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

Asap: a framework for over-representation statistics for transcription factor binding sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

JASPAR, the open access database of transcription factor-binding profiles: new content and tools in the 2008 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

TRANSFAC and its module TRANSCompel: transcriptional gene regulation in eukaryotes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

The Connectivity Map: a new tool for biomedical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

ExPASy: The proteomics server for in-depth protein knowledge and analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

Gene selection and classification of microarray data using random forest.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

E2F repression by C/EBPalpha is required for adipogenesis and granulopoiesis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBP alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

Gene expression changes associated with progression and response in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

The myeloid zinc finger gene (MZF-1) delays retinoic acid-induced apoptosis and differentiation in myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

The t(1;12)(q21;p13) translocation of human acute myeloblastic leukemia results in a TEL-ARNT fusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

The transcription factor EGR1 controls both the proliferation and localization of hematopoietic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

Oncogenic action of secreted phospholipase A2 in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL9

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

Molecular profiling reveals myeloid leukemia cell lines to be faithful model systems characterized by distinct genomic aberrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

Molecular basis of parthenolide-dependent proapoptotic activity in cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

Modeling of C/EBPα Mutant Acute Myeloid Leukemia Reveals a Common Expression Signature of Committed Myeloid Leukemia-Initiating Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

Identification of a myeloid committed progenitor as the cancer-initiating cell in acute promyelocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

PML-RARalpha initiates leukemia by conferring properties of self-renewal to committed promyelocytic progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

Anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

PI3K pathway alterations in cancer: variations on a theme

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

Phospholipase A2 as targets for anti-cancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

Group VI phospholipases A2: homeostatic phospholipases with significant potential as targets for novel therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

Control of the growth of human breast cancer cells in culture by manipulation of arachidonate metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

Calcium-independent phospholipase A2 mediates proliferation of human promonocytic U937 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

Gene expression-based high-throughput screening(GE-HTS) and application to leukemia differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

7 January 2021

A Model-Based Background Adjustment for Oligonucleotide Expression Arrays

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

7 January 2021

Mechanisms of Disease: cancer stem cells--targeting the evil twin

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

7 January 2021

PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

7 January 2021

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.95

7 January 2021

Identifiers

DOI

10.1038/LEU.2010.95

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20508621%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

1 reference